Participated · Series A · Jun 2026

Straiker provides an agentic-native security platform with three integrated capabilities: comprehensive discovery of AI agents across enterprise environments, pre-deployment adversarial testing to surface vulnerabilities, and runtime protection that monitors activity and stops threats. The founding team includes veterans of Palo Alto Networks and AI/security research, and the company emphasizes a shared intelligence layer that uses production detections to strengthen testing and protections. Since launching in 2025, Straiker has become a partner to frontier AI labs and Fortune 500 enterprises and reports run-rate revenue growth of more than 15x in less than a year. Straiker operates STAR Labs, its dedicated AI threat research arm, which informs its defenses and provides early visibility into emerging attack techniques.

Participated · Series A · Jun 2026

Bionyra is advancing a pipeline of next-generation mono- and multispecific antibodies engineered with half-life extension to target immune pathways in diseases with high unmet need. Lead programs include BYN-002, a TL1A monoclonal antibody in a fully enrolled Phase 1 in healthy subjects; BYN-003, a TL1A*IL-23p19 bispecific that entered Phase 1 in April; and BYN-001, an IL-25 monoclonal antibody in IND-stage for atopic dermatitis and type 2 inflammation. The company holds exclusive global rights to these assets outside Greater China through licenses from TrueLab Biopharmaceutical and NovaRock Biotherapeutics, and is progressing additional preclinical assets. Bionyra was co-founded and seed financed by Sofinnova Partners and is led by CEO Frédéric Marrache, a former Sanofi R&D executive with experience in immunology and inflammation. The company plans to use its Series A proceeds to advance clinical development and rapidly generate clinical validation in dermatology and inflammatory bowel disease.

Participated · Seed · Apr 2026

AIBuildAI was founded by Pengtao Xie and his students to develop AI agents that can automatically construct AI models, aiming to let users build models without coding or AI expertise. Its Agent 1.0 achieved first place on the OpenAI MLE-Bench, and the company announced an upcoming Agent 2.0. The team announced a $4 million pre-seed raise to support its mission, with backing from Sixty Degree Capital, ML Capital, and angel investors. Public acknowledgments named individual supporters including Mohan Zhang, mehreen m, ROBERT GUO, and Patrick Dai. The company framed its long-term vision around accessibility of AI while raising questions about ensuring quality and ethics if model-building is widely democratized. No revenue, user metrics, founding year, or location were disclosed in the announcement.

Participated · Series B · Mar 2026

Crossbow Therapeutics is developing a portfolio of T-Bolt™ T-cell engager (TCE) therapies built from T-cell receptor-mimetic antibodies that target peptide–HLA (pHLA) complexes on cancer cells. Its lead program, CBX-250, is a first-in-class TCE targeting a pHLA specific to myeloid cancer cells and is being evaluated in the ongoing CROSSCHECK-001 Phase 1 trial in relapsed and refractory myeloid malignancies. The company is advancing CBX-663, a TCE targeting a TERT-derived pHLA, toward IND submission and a planned Phase 1 start in Q3 2026 for multiple hematologic and solid tumors. Crossbow positions its T-Bolt™ platform as broadly adaptable to address intracellular cancer targets previously unreachable by antibodies. The company will present preclinical data for both programs at the AACR 2026 Annual Meeting and expects initial clinical data from CBX-250 around the end of 2026. The recent $77 million Series B is intended to fund completion of CBX-250’s Phase 1 and to accelerate initiation and development of additional T-Bolt™ programs.

Participated · Series E · Mar 2026

HawkEye 360 operates a constellation of satellites that detect, geolocate, and characterize radio-frequency (RF) emissions around the globe. Its proprietary signal processing and AI-driven analytics platform converts raw RF spectrum data into actionable intelligence for government and allied defense agencies. The company positions its offering as mission-critical for domain awareness and early-warning needs, enabling faster and better decision-making. HawkEye 360 is currently integrating Innovative Signal Analysis (ISA) to deepen its analytic capabilities and expand its product suite. Proceeds from recent fundraising are earmarked to strengthen the balance sheet and support this integration, as well as to continue investing in platform enhancements. Headquartered in Herndon, Virginia, the firm markets itself as a trusted partner proven by operational mission success.